Articles tagged with Macular Degeneration
A new human stem cell model has been developed to study macular degeneration, a leading cause of vision loss in older adults. The model, created by researchers at the University of Rochester Medical Center, mimics key characteristics of the disease and could lead to new avenues of research and potential drug targets.
Dr. McKay's research has shown that l-dopa can delay or prevent macular degeneration in individuals with Parkinson's disease. He will now investigate the role of dopamine signaling pathways in AMD prevention.
A study found that Swedish optometrists recommend nutritional supplements, dietary changes, and smoking cessation to patients at risk of or with early symptoms of AMD. Optometrists were more likely to provide advice on diet compared to ophthalmologists.
A nutraceutical called Longevinex has been shown to reduce the time it takes for older eyes to adapt to the dark, predicting future onset of macular degeneration. The study found that 12 out of 14 eyes tested improved or were stable after using Longevinex.
Researchers found significant ethnic differences in visual function among Chinese, Malay, and Indian participants with age-related macular degeneration. Visual acuity was poorer in Chinese participants with early or late AMD, while Malay participants showed a trend of worsening visual function with increasing AMD severity.
A study published in JAMA Ophthalmology found that patients with age-related macular degeneration who received seven or more eye injections of bevacizumab annually had a higher risk of developing moderate to advanced glaucoma. This increased risk was associated with the potential for elevated intraocular pressure, highlighting the need...
A new study from Johns Hopkins Medicine found that in-home occupational therapy significantly reduces the severity of depression in patients with central vision loss. The therapy, which includes training on daily activities like cooking and reading, is more effective than supportive therapy in improving mental health outcomes.
Researchers are testing a new treatment using cells derived from umbilical cord tissue to target age-related macular degeneration. The therapy aims to prevent further loss of rod and cone cells and potentially restore vision in patients with advanced dry macular degeneration.
A study published in PNAS highlights two protective mechanisms compromised in macular degeneration. Drugs that target immune abnormalities and cholesterol levels may slow or prevent the condition, which affects 2 million Americans.
A miniature camera using optical character-recognition technology mounted on eyeglasses significantly improves the ability to read and perform daily living activities. The device, called OrCam, recognizes text, faces, and commercial products, offering a new hope for those with age-related macular degeneration or advanced-stage glaucoma.
The BrightFocus Foundation has awarded nearly $5 million in vision research grants to five scientists studying macular degeneration and glaucoma. The grants, named after prominent leaders in the field, will support innovative research projects aimed at understanding and preventing these diseases.
A University of Arizona-led study found that patients taking levodopa, a treatment for Parkinson's disease, are less likely to develop macular degeneration. The study suggests l-dopa may delay or prevent the disease, potentially leading to new treatments and improved eye health.
Researchers have discovered a potential link between Parkinson's treatment and protection against age-related macular degeneration (AMD), the most common form of blindness. The study suggests that patients taking L-DOPA as Parkinson's treatment may be less likely to develop AMD, with delayed or prevented disease progression.
A study published in Optometry and Vision Science found that patients with age-related macular degeneration can accurately complete touch screen tasks, but their performance is slowed due to difficulties exploring the interface. The research suggests adapting touch screen applications to aid individuals with AMD.
Researchers identified a pathway that leads to atypical blood vessel formation in age-related macular degeneration. Inhibiting this pathway may halt or restore sight in people with the disease.
Researchers discovered that a low-energy nanosecond laser therapy can reverse the pathological and molecular changes in age-related macular degeneration. The treatment does not cause retinal damage, and it may also be effective on other eye diseases like diabetic macular oedema.
Scientists at Florida Atlantic University have discovered that sulindac can protect against oxidative damage due to age-related macular degeneration. This finding suggests an inexpensive and relatively non-toxic therapeutic approach for treating this condition.
A study of 4,379 participants found that having AMD in one eye increases the risk of developing AMD in the other eye, with more severe disease progressing faster. The researchers tracked AMD severity in both eyes over a 20-year period and found a strong correlation between the two eyes.
Researchers have created a high-resolution molecular map of the choroid, supplying blood and oxygen to the outer retina, revealing patterns of protein abundance that may be critical in vision loss. The map helps explain why certain areas are more susceptible to disease and identifies potential treatment targets.
Research shows higher education levels and more years spent in school are associated with a greater prevalence and severity of nearsightedness. Outdoor activity and exposure to daylight are linked to reduced risk of myopia, suggesting environmental factors may outweigh genetics in its development.
A long-term population-based cohort study found that using vasodilators was associated with a 72% greater risk of developing early-stage AMD. Oral beta blockers were also linked to an increased risk of neovascular AMD, a more advanced and vision-threatening form.
Researchers found that a 'treat and extend' strategy can reduce the average number of visits and injections from 12 to 8.3 times per year for patients with age-related macular degeneration. This approach could lower the financial burdens on patients, families, and government.
The BrightFocus Foundation has honored five outstanding scientists in the fields of macular degeneration and glaucoma. Researchers from California, Florida, Maryland, Michigan, and Texas received $3.5 million in grant awards to study new treatments for these eye diseases.
A large clinical trial found no significant reduction in cardiovascular disease (CVD) events among elderly patients taking daily supplements of omega-3 fatty acids and lutein/zeaxanthin for age-related macular degeneration. The study involved 4,203 participants and found no benefit from these supplements on CVD outcomes.
A recent study has identified a rare gene mutation linked to age-related macular degeneration (AMD), the leading cause of blindness in Americans over 50. The C3 gene variant contributes to AMD risk by interfering with the complement pathway's normal function.
Researchers at UNC School of Medicine have found a class of drugs known as MDM2 inhibitors effective in regressing abnormal blood vessels responsible for vision loss associated with macular degeneration. The treatment has potential to reduce the burden on patients and physicians.
Researchers found that people with normal vision can adjust their eye movements within hours to cope with temporary vision loss. This discovery suggests a way to help individuals with age-related macular degeneration better manage visual impairment.
A study published in Human Molecular Genetics found that the complement system plays a critical role in early macular degeneration. The researchers used mice genetically engineered to have an inherited form of the disease and found that turning off the complement system prevented the disease from progressing.
Bioengineering professor Dimitrios Morikis and research scientist Monte Radeke are searching for chemical compounds targeting the complement system to treat age-related macular degeneration. They will use computational screening, experimental testing, and human retinal cell-based models to identify potential treatments.
Age-related macular degeneration is a leading cause of visual impairment in people over 65, affecting over 9.1 million Americans. Regular screening by an ophthalmologist is critical for early detection and treatment.
Researchers found that age-related macular degeneration shares a common link with atherosclerosis due to impaired cholesterol efflux in macrophages. The study suggests that cholesterol-lowering eye drops or other medications could prevent vision loss caused by macular degeneration.
A study published in Cell Metabolism suggests that macrophage cholesterol accumulation contributes to macular degeneration. Researchers found that eye drops could reduce blood vessel growth and prevent blindness by targeting cholesterol regulators.
A study published in PLOS Medicine found that age-related macular degeneration is prevalent in Kenya, causing visual impairment and blindness. The condition was detected in 12.4% of the population aged over 50, with advanced stages found in 1.2%.
Researchers at LSU Health Sciences Center have identified a protein, fatty acid transport protein 4 (FATP4), that protects retinal photoreceptor cells from degeneration. The study suggests FATP4 may be a therapeutic target for inherited retinal degenerative diseases and age-related macular degeneration.
A study of over 2,300 participants found that regular aspirin use was associated with a higher risk of developing neovascular age-related macular degeneration. Aspirin use increased the risk by 1.9% at 15 years compared to non-users.
Scientists at Sanford-Burnham Medical Research Institute have discovered that carnosic acid, a component of rosemary, promotes eye health and protects retinas from degeneration. The findings suggest a possible new approach for treating age-related macular degeneration.
A Mayo Clinic study finds that a primary treatment for wet macular degeneration is effective even in patients with macular traction problems. This breakthrough may help physicians not give up on treating such patients, and understand the need for more doses of medication.
University of Kentucky researchers have identified a major breakthrough in treating geographic atrophy, an untreatable form of age-related macular degeneration. They found that blocking specific pathways can prevent retinal degeneration and vision loss, paving the way for a new potential therapy.
According to a Northwestern University study, the prevalence of visual impairment in adults aged 65 and older decreased by 58% between 1984 and 2010. Improved cataract surgery techniques and reduced smoking rates are likely contributing factors.
Researchers report a breakthrough treatment for invasive macular degeneration, using an oral nutriceutical that rapidly restores vision and improves overall eye health. In 16 successful cases, the treatment showed significant improvements in visual acuity, contrast vision, and circulatory health within 3-6 weeks.
A major breakthrough in treating geographic atrophy, a form of age-related macular degeneration, has been made by University of Kentucky researchers. The discovery highlights the role of the NLRP3 inflammasome and MyD88 in triggering vision loss due to retinal pigmented epithelial cell death.
The presentation presents one-year IVAN and two-year CATT trial results evaluating the efficacy of Lucentis and Avastin in treating age-related macular degeneration. The studies demonstrate Lucentis' effectiveness in reducing edema and improving vision.
Scientists at Trinity College Dublin have found that controlling IL-18 levels could prevent the development of wet AMD, a form of blindness. Drs. Sarah Doyle and Matthew Campbell discovered that drusen accumulating in the macula lead to IL-18 production, which acts as an anti-angiogenic factor.
Researchers have identified over 50 genes linked to age-related macular degeneration, including those involved in inflammation and wound healing. These findings may lead to new diagnostic methods and treatment targets for the disease.
The ARVO Foundation for Eye Research has awarded $40,000 fellowships to Balamurali K. Ambati and Stephen H. Tsang to conduct age-related macular degeneration (AMD) research. The fellowships aim to develop therapeutics and personalized medicine approaches for AMD.
Researchers used human embryonic stem cells to treat macular degeneration in two patients, with some improvement in vision observed. The study showed that the transplants were safe and led to successful engraftment of cells into the retina.
Researchers have developed an intracellular, sustained-release drug delivery system using nanoparticles called dendrimers, targeting neuroinflammation in the retina. The treatment protects vision by preventing injury to photoreceptors and reduces neuroinflammation, providing potential relief for millions of patients worldwide.
Dimitrios Morikis and Lincoln Johnson aim to create new inhibitors of the complement system to treat the disease, which affects over 1.75 million Americans. The researchers will use computational modeling and virtual screening to identify potential treatments.
A new risk assessment model predicts development of advanced age-related macular degeneration (AMD) in individuals with early symptoms. The model identifies phenotypic, demographic, environmental, and genetic risk factors, accurately predicting progression and helping determine follow-up examinations and preventive measures.
A twin study found that a diet rich in vitamin D, betaine, and methionine may slow macular degeneration progression. Higher smoking rates were linked to increased disease severity.
A computer modeling study suggests that ranibizumab can reduce the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white individuals. The model estimated that monthly ranibizumab usage could prevent 16,268 cases of legal blindness and 34,702 cases of visual impairment.
Researchers at Columbia University Medical Center have discovered a modified form of vitamin A that slows the formation of detrimental dimers, leading to improved vision and ocular health in mice with Stargardt's disease. The study provides hope for treating age-related macular degeneration and Stargardt's disease.
Researchers at Tufts University School of Medicine developed a gene therapy approach that significantly reduces uncontrolled blood vessel growth and cell death typical of AMD, slowing its progression. The treatment uses CD59 to block the formation of 'membrane attack complex' in cell membranes.
Women under 75 with high vitamin D levels have lower risk of early age-related macular degeneration (AMD), while those with low levels are at increased risk. The study found that women with 25-hydroxyvitamin D concentrations above 38 nanomoles per liter had a 44% decreased odds of developing AMD.
Research suggests that high vitamin D levels are associated with a reduced risk of early age-related macular degeneration (AMD) in women under 75. Higher vitamin D intake from food and supplements is linked to lower AMD risk, while sun exposure does not show a significant correlation.
Researchers at Georgetown University Medical Center have successfully created retinal cells derived from human-induced pluripotent stem cells that mimic the eye cells responsible for age-related macular degeneration. The discovery paves the way for potential treatment and regeneration therapies for this debilitating condition.
A large population study found that regular consumption of fish and omega-3 fatty acids was associated with a significantly reduced risk of developing age-related macular degeneration in women. The study, published in Archives of Ophthalmology, found that higher intake of DHA and EPA was linked to a 38% lower risk of the condition.
Research finds late-stage age-related macular degeneration associated with a 56% increased risk of any type of stroke. Specifically, late AMD was strongly linked to over six times the risk of brain hemorrhage but not with brain infarction, according to a study presented at the American Stroke Association's International Stroke Conference.
The study found an estimated 6.5% of Americans aged 40 and older have age-related macular degeneration, a decline from the 1988-1994 survey's 9.4%. Non-Hispanic black individuals had lower AMD prevalence than non-Hispanic white individuals.
The Ontario Genomics Institute is investing in ArcticDx's Macula Risk test, which detects genetic variations predicting AMD progression. The test may help target effective care to those who need it most and relieve uncertainty for others.